CORONA REMEDIES LIMITED DCF Valuation
CORONA · Healthcare · Current price ₹2,050.1
CORONA REMEDIES LIMITED intrinsic-value estimate
Our intrinsic-value model estimates CORONA REMEDIES LIMITED is worth ₹200 per share, based on 25% ROE fading to 12% over ~10 yrs, on ₹122 book. Rather than a raw DCF — which is highly sensitive to fragile cash-flow forecasts — we use a residual-income (excess-return) model: a company is worth its book value plus the present value of the returns it earns ABOVE its cost of equity. A narrow economic moat sets how long that edge is assumed to last.
Try your own assumptions
Prefer a classic discounted-cash-flow view? Open the DCF calculator below — it pre-fills CORONA REMEDIES LIMITED's real free cash flow, net debt and share count so you can model your own growth and discount-rate scenario in seconds.
More on CORONA REMEDIES LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.